Home    About Us    Medic-All    Bio B2B    Hot Topic     Expo     Login | Join Now          
Bio B2B 〉EirGenix, Inc.

EirGenix, Inc.

Chat Now My Favorites
EirGenix is a Biologic Drug Development Company, and a Contract Development and Manufacturing Organization (CDMO).  Current pipelines involve seven products in development ranging from discovery to clinical, such as HER2 family biosimilars, antibody-drug conjugates (ADCs), and carrier protein for vaccine therapy.

EirGenix provides high quality and cost-effective service, supporting our clients in process development, analytical testing, and cGMP manufacturing of biopharmaceuticals from pre-clinical to commercial manufacturing. Our facility is located in Taiwan and we hold a US FDA Drug Master File.  

EirGenix, Inc. forms a strategic alliance with Formosa Laboratories, Inc. to provide one-stop solution for antibody drug conjugates (ADC) development project. In which Formosa Laboratories handles the small molecule development of linker and high potency payload (cytotoxic compound), while EirGenix delivers large molecule parts, such as monoclonal antibody or protein with specific targeting.

EirGenix aims to contribute to our partners' success as our priority, through tailoring the services and delivery to the exact needs of our clients. EirGenix acquired Development Center for Biotechnology (DCB) Biophamacutical Pilot Plant Facility in 2013, and currently growing at a fast speed to serve the increasing demands of biopharmaceutical drug substance.

The new commercial biomanufacturing facility will be located at Zhubei Biomedical Science Park. There are a 12 x 2,000L Mammalian and a 1,000L Microbial process trains.  Our commercial facility will be the largest biomanufacturing plant in Taiwan. Our goal is to become the new hub in Asia for biologic product development and manufacturing, while developing new collaborations and partnerships with pharmaceutical companies around the world.

Mission Statement
Providing the clients with high quality and cost-effective services, concurrently developing biologic products (e.g. ADC, biosimilar, biobetter) with partners, to benefit the community and society as a whole.

Awards
- First Place of Biomedical Award, Taiwan Healthcare and Agricultural Biotech Industries Innovation and Excellence Awards 2015
- Development of Innovative ADC Technology and Production Platform, Asia-Pacific Bioprocessing Excellence Awards 2017 
- Best Bioprocessing Excellence in Taiwan, Asia-Pacific Bioprocessing Excellence Awards 2017
- Emerging Company of the Year, Taiwan Bio Industry Organization Awards 2017 
  • Lee-Cheng (L-C) Liu,<br/>President & CEO

    Lee-Cheng (L-C) Liu,
    President & CEO

    Over 30-yrs experience,
    Ex-President & COO of AnGes Inc.
    Ph.D., Chemical Engineering & Applied Chemistry, Columbia University
  • You-Nan Shih, <br/>Sr VP, Quality System

    You-Nan Shih,
    Sr VP, Quality System

    Over 25-yrs experience,
    Ex-VP Quality of ScinoPharm Taiwan,
    Ph.D., Chemistry, Cornell University
  • Thomas Schulze,<br/>Unit VP, Product Dev

    Thomas Schulze,
    Unit VP, Product Dev

    Over 25-yrs experience,
    Ex-CEO of Formycon and Avontec,
    Ph.D., Max-Planck Institute for Molecular Genetics, Freie Universität Berlin
  • Chih-Jung (CJ) Chang,<br/>Unit VP, CDMO

    Chih-Jung (CJ) Chang,
    Unit VP, CDMO

    Over 20-yrs experience,
    Ex-Director of TOT Oncology Business Unit at TTY, Ph.D., Organic Chemistry, National Taiwan University
  • Frank Ho, <br/>VP, Manufacturing

    Frank Ho,
    VP, Manufacturing

    Over 20-yrs experience,
    Ex-Head of Technical Operations at A-Bio Pharma (Singapore), experience at Fibrogen, Applied Biosystems, BioMarin; Ph.D., UC Davis
EirGenix is a Biologic Drug Development Company, and a Contract Development and Manufacturing Organization (CDMO).  Current pipelines involve seven products in development ranging from discovery to clinical, such as HER2 family biosimilars, antibody-drug conjugates (ADCs), and carrier protein for vaccine therapy.

EirGenix provides high quality and cost-effective service, supporting our clients in process development, analytical testing, and cGMP manufacturing of biopharmaceuticals from pre-clinical to commercial manufacturing. Our facility is located in Taiwan and we hold a US FDA Drug Master File.  

EirGenix, Inc. forms a strategic alliance with Formosa Laboratories, Inc. to provide one-stop solution for antibody drug conjugates (ADC) development project. In which Formosa Laboratories handles the small molecule development of linker and high potency payload (cytotoxic compound), while EirGenix delivers large molecule parts, such as monoclonal antibody or protein with specific targeting.

EirGenix aims to contribute to our partners' success as our priority, through tailoring the services and delivery to the exact needs of our clients. EirGenix acquired Development Center for Biotechnology (DCB) Biophamacutical Pilot Plant Facility in 2013, and currently growing at a fast speed to serve the increasing demands of biopharmaceutical drug substance.

The new commercial biomanufacturing facility will be located at Zhubei Biomedical Science Park. There are a 12 x 2,000L Mammalian and a 1,000L Microbial process trains.  Our commercial facility will be the largest biomanufacturing plant in Taiwan. Our goal is to become the new hub in Asia for biologic product development and manufacturing, while developing new collaborations and partnerships with pharmaceutical companies around the world.

Mission Statement
Providing the clients with high quality and cost-effective services, concurrently developing biologic products (e.g. ADC, biosimilar, biobetter) with partners, to benefit the community and society as a whole.

Awards
- First Place of Biomedical Award, Taiwan Healthcare and Agricultural Biotech Industries Innovation and Excellence Awards 2015
- Development of Innovative ADC Technology and Production Platform, Asia-Pacific Bioprocessing Excellence Awards 2017 
- Best Bioprocessing Excellence in Taiwan, Asia-Pacific Bioprocessing Excellence Awards 2017
- Emerging Company of the Year, Taiwan Bio Industry Organization Awards 2017 
  Video
  Video